Scarica l'app Stockscreener
4.27
4.15%
0.17
Dopo l'orario di chiusura:
4.20
-0.07
-1.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AVXL Giù?
Forum
Previsione
Frazionamento azionario
Anavex Life Sciences Corporation Borsa (AVXL) Ultime notizie
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - PR Newswire
Will Anavex Life Sciences Corp. stock continue upward momentum2025 Stock Rankings & Daily Stock Trend Watchlist - ulpravda.ru
Is Anavex Life Sciences Corp. stock a buy for dividend growth2025 Major Catalysts & Free Real-Time Volume Trigger Notifications - ulpravda.ru
Anavex Life Sciences Appoints Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology - Quiver Quantitative
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - Anavex Life Sciences
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Shares Surge on Encouraging Regulatory Development - AD HOC NEWS
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - Anavex Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL - FinancialContent
Anavex Life Sciences (AVXL) Receives Reaffirmed Buy Rating from D. Boral Capital | AVXL Stock News - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. Invited by FDA to Present Alzheimer’s Disease Clinical Trial Results - Quiver Quantitative
FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Prime Publishers, Inc.
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What analysts say about Anavex Life Sciences Corp stockHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - earlytimes.in
Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright - MarketBeat
Can Anavex Life Sciences Corp. stock sustain free cash flow growth2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Can Anavex Life Sciences Corp. stock resist market sell offs2025 Valuation Update & Weekly Watchlist for Consistent Profits - DonanımHaber
Rate Cut: Why Anavex Life Sciences Corp stock could be next big winner2025 Trading Volume Trends & Accurate Buy Signal Notifications - moha.gov.vn
AVXL Maintains Buy Rating with Price Target Unchanged at $24 by D. Boral Capital | AVXL Stock News - GuruFocus
Why Anavex Life Sciences Corp. stock could rally in 2025Stock Surge & Risk Controlled Swing Trade Alerts - ulpravda.ru
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's. Read more here. - Seeking Alpha
Anavex Life Sciences Requests European Medicines Agency to Re-evaluate Blarcamesine as Early Alzheimer's Treatment - marketscreener.com
What catalysts could drive Anavex Life Sciences Corp. stock higher2025 Institutional Moves & Technical Pattern Recognition Alerts - Улправда
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - The Manila Times
Anavex Life Sciences requests EMA to re-examine blarcamesine for Alzheimer's - marketscreener.com
EU regulators asked to revisit an experimental pill for early Alzheimer’s - Stock Titan
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Anavex Life Sciences (AVXL): Analyst Ratings Update for December 15, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital - MarketBeat
Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday - Defense World
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences Updates on Regulatory Review for Blarcamesine in Treating Early Alzheimer's Disease - Quiver Quantitative
Anavex (NASDAQ: AVXL) to seek CHMP re-exam after EU negative view on blarcamesine - Stock Titan
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025) - ts2.tech
Anavex (AVXL) Faces EMA Setback on Alzheimer's Drug Application - GuruFocus
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):